Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 649

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 649
---
 ​                              | ​ |  55,000 | ​ | ​ | ​ | ​                    | ​ | 100,000 | ​ | ​ | ​ | ​                     | ​ | 100,000 | ​ | ​ | ​ | ​        | $ | 255,000 | ​ | ​ |
| Susan Shiff, Ph.D.     | ​ | ​ | ​                              | ​ |  62,500 | ​ | ​ | ​ | ​                    | ​ | 100,000 | ​ | ​ | ​ | ​                     | ​ | 100,000 | ​ | ​ | ​ | ​        | $ | 262,500 | ​ | ​ |
| Helen M. Boudreau      | ​ | ​ | ​                              | ​ |  70,000 | ​ | ​ | ​ | ​                    | ​ | 100,000 | ​ | ​ | ​ | ​                     | ​ | 100,000 | ​ | ​ | ​ | ​        | $ | 270,000 | ​ | ​ |

(1) Amounts reflect the annual fees paid to all non-employee directors for their service on Cara’s Board, including for their committee membership and service as Lead Independent Director or Chair of a committee, under Cara’s non-employee director compensation policy, as described below in more detail. (2) Amounts reflect the aggregate grant date fair value of options and stock awards granted during 2024 calculated in accordance with ASC Topic 718. The assumptions Cara uses in calculating the grant date fair value of stock options are substantially similar to those set forth in Note 15 to Cara’s unaudited condensed financial statements for the quarter ended September 30, 2024 included elsewhere in this proxy statement/prospectus. These amounts do not reflect the actual economic value that may be realized by the non-employee director. (3) The following table sets forth the aggregate number of unvested RSUs and the aggregate number of shares underlying stock options held by Cara’s non-employee directors held as of December 31, 2024 by each non-employee director who was serving as of December 31, 2024:

| Director               | ​ | ​ | RSUs |   |        |   | ​ | ​ | Number ofSharesUnderlyingOptions |   |        |   | ​ |
| Jeffrey L. Ives, Ph.D. | ​ | ​ | ​    | ​ | 12,553 | ​ | ​ | ​ | ​